Merck & Co., Inc. (MRK)

NYQ – Real Time Price. Currency in USD

131.87

+1.45 (1.11%)

Market open: Aug 12, 2026, 10:18 AM EDT

130.07

-0.35 (-0.27%)

Previous after-hours: Aug 11, 2026, 7:49 PM EDT

07.08.2026

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

06.08.2026

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.

06.08.2026

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

06.08.2026

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.

05.08.2026

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.

05.08.2026

Merck & Co., Inc. Q2 Earnings Call Highlights

Merck & Co., Inc. NYSE: MRK reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield.

04.08.2026

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.

Videos

No Data

There is no data to display

Press releases

06.08.2026

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

04.08.2026

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results.

Merck & Co., Inc. (MRK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Merck & Co., Inc. (MRK)

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck & Co., Inc. Q2 Earnings Call Highlights

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Videos

No Data

Press releases

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck & Co., Inc. Q2 Earnings Call Highlights

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Videos

No Data

Press releases

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Search stocks

Merck & Co., Inc. (MRK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Merck & Co., Inc. (MRK)

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck & Co., Inc. Q2 Earnings Call Highlights

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Videos

No Data

Press releases

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck & Co., Inc. Q2 Earnings Call Highlights

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Videos

No Data

Press releases

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline